Active substancePhospholipidsPhospholipids
Similar drugsTo uncover
  • Antralive®
    capsules inwards 
  • L'esfal
    solution in / in 
    FARMAK, PAO     Ukraine
  • Livenciale
    solution in / in 
    Rowecq Limited     United Kingdom
  • Livolife Forte
    capsules inwards 
    KORAL-MED, CJSC     Russia
  • Phosphontsiale®
    capsules inwards 
  • Phosphontsiale® Mono
    solution in / in 
    Bakter, OOO     Russia
  • Essentiale® H
    solution in / in 
  • Essentiale® Fort H
    capsules inwards 
  • Essential phospholipids
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley forte
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley®
    solution in / in 
  • Dosage form: & nbspcapsules
    Composition:

    1 capsule contains:

    Active substance: the lipoid of PPL-400 is 400.0 mg, in terms of polyunsaturated phospholipids from soya lecithin (fraction PPL) - 300.0 mg, with an average content L-alpha-phosphatidylcholine 76% - 228.0 mg.

    Excipients: Ethyl alcohol 95% - 4.0 mg.

    Hard gelatin capsules โ„– 0:

    The composition of the capsule body: iron dye oxide black - 0.01%, iron dye oxide red 0.01%, iron dye oxide yellow 0.1714%, titanium dioxide 3%, gelatin 100%;

    The composition of the capsule cap: iron oxide, black oxide - 0.53%, iron oxide red oxide - 0.93%, iron oxide oxide yellow 0.2%, titanium dioxide 0.3333%, gelatin 100%

    Description:

    Capsules hard gelatinous โ„– 0.

    The capsule case is light brown with a beige hue, the lid capsule is dark brown.

    The contents of the capsules are a yellow-brown or brown homogeneous mass from a greasy to a more dense consistency with a characteristic odor.

    Pharmacotherapeutic group:Hepatoprotective agent
    ATX: & nbsp

    A.05.C   Combination of drugs for the treatment of diseases of the liver and biliary tract

    Pharmacodynamics:

    Essential phospholipids are the basic elements of the structure of the cell membrane and cellular organelles of the liver. In diseases of the liver, there is always damage to the membranes of the liver cells and their organelles, which leads to disturbances in the activity of the enzymes and receptor systems associated with them, impairment of the functional activity of the hepatic cells, and a decrease in the ability to regenerate.

    Phospholipids, which are part of Essley forte, correspond in their chemical structure to endogenous phospholipids, but exceed endogenous phospholipids by activity due to the higher content of polyunsaturated (essential) fatty acids in them.The incorporation of these highly energetic molecules into the damaged sections of the cell membranes of hepatocytes restores the integrity of the hepatic cells, promotes their regeneration. Cis-double bonds of their polyunsaturated fatty acids prevent the parallel arrangement of hydrocarbon chains in the phospholipids of cell membranes, the density of the phospholipid structure of the cell membranes of hepatocytes decreases, which causes an increase in their fluidity and elasticity, improves metabolism. The resulting functional blocks increase the activity of enzymes fixed on the membranes and promote the normal, physiological pathway of the most important metabolic processes.

    Phospholipids, which are part of the Essley forte preparation, regulate the metabolism of lipoproteins, transferring neutral fats and cholesterol to oxidation sites, mainly by increasing the ability of high-density lipoproteins to bind to cholesterol.

    Thus, there is a normalizing effect on the metabolism of lipids and proteins; on the de-toxication function of the liver andphospholipid-dependent enzyme systems; which ultimately prevents the formation of connective tissue in the liver and promotes the natural recovery of liver cells.

    In the excretion of phospholipids in bile there is a decrease in the lithogenic index and stabilization of bile.

    Pharmacokinetics:

    More than 90% of the ingested phospholipids are absorbed in the small intestine. Most of them are cleaved by phospholipase A up to 1-acyl-lysophosphatidylcholine, 50% of which immediately undergoes reverse acetylation to polyunsaturated phosphatidylcholine during the absorption process in the intestinal mucosa. This polyunsaturated phosphatidylcholine with shock lymph enters the bloodstream and from there, mainly associated with high density lipoproteins to the liver form.

    Studies of pharmacokinetics in humans were conducted using dilanololephosphatidylcholine with a radioactive label (3H and 14C). The choline part was labeled with 3H, and the remainder of the lipolic acid had a 14C label. The maximum concentration of 3H is reached 6-24 hours after administration and is 19.9% โ€‹โ€‹of the prescribed dose. The half-life of the choline component is 66 hours.The maximum concentration of 14C is reached 4-12 hours after administration and is up to 27.9% of the prescribed dose. The half-life of this component is 32 hours.

    Both isotopes are absorbed more than 90% in the intestine

    Indications:

    Chronic hepatitis, cirrhosis, fatty degeneration of the liver of various etiologies, toxic liver damage, alcoholic hepatitis, impaired liver function in other somatic diseases. Toxicosis of pregnancy, prevention of recurrences of gallstones, psoriasis (as a means of supporting therapy), radiation syndrome.

    Contraindications:

    Individual intolerance to phosphatidylcholine or other auxiliary components of the drug. Intolerance to soy. Children under 12 years of age (lack of sufficient evidence base).

    Dosing and Administration:

    Inside. Capsules should be taken whole, washed down with a sufficient amount of water (approximately, 1 glass).

    For adolescents over 12 years of age and weighing more than 43 kg, as well as for adults, Essyla forte preparation is recommended to take 2 capsules - 3 times daily with meals.

    As a rule, the duration of application is not limited.

    Side effects:

    Esslial forte preparation is usually well tolerated by patients. To assess the frequency of side effects, the following definitions are used: very often (> 1/10), often (> 1/100 - <1/10), often (> 1/1000 - <1/100), rarely (>1/10000 - <1/1000), ochen rarely (<1/10000), unknown frequency (it is impossible to determine the frequency of occurrence from the available data).

    From the gastrointestinal tract: rarely - discomfort in the epigastric region, loosening of the stool, nausea, gastralgia.

    Allergic reactions: very rarely - rashes, exanthema, urticaria; unknown frequency - itching.

    Overdose:no information
    Interaction:no information
    Effect on the ability to drive transp. cf. and fur:no information
    Form release / dosage:

    Capsules of 300 mg.


    Packaging:

    For 5, 6, 10 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    For 10, 20, 30, 40, 50, 60, 90 or 100 capsules in cans of polyethylene terephthalate or in polymer cans for medicines.

    One bank or 1,2, 3, 4, 5, 6, 9 or 10 contour cellular packs, together with the instruction for use, are placed in a cardboard package (bundle).

    It is allowed to bundle 2 or 3 cardboard packages (packs) into a group package (shipping container) from cardboard for consumer packaging.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Hs applied after the expiration date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002933
    Date of registration:30.03.2015
    The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp28.10.2015
    Illustrated instructions
      Instructions
      Up